Framing: separate a pharmacy transfer from a change in medicine, formulation, concentration or device. LillyDirect states that medicine or formulation changes require a new valid prescription and that dose changes come from the prescriber. FDA’s compounded-semaglutide alert documents the risks of concentration and measurement confusion. (lilly.com)
Put to: Robert Kushner and Michael Ganio.
Buyer owner: Medical director, with the COO managing execution.
Why it matters: Procurement should organise continuity while leaving patient-specific treatment decisions with clinicians.
A good answer should cover:
- Identifying patients awaiting supply, holding existing supply or requiring clinical review.
- Confirming whether a transfer, new prescription, new counselling or different instructions are needed.
- Reconciling outstanding orders, payments and shipments to prevent duplicates.
- Clinician-led management of interruptions, product changes and restart questions.
- Patient communications that distinguish the dispensing change from any clinical change.
Follow-up that tests the answer: “Which patients should not enter a bulk migration workflow, and what information must the reviewing clinician have?”
Evidence to request: A clinician-approved migration protocol, exception queue and patient communication pack. Require a controlled pilot and reconciliation before broad rollout; do not create an automatic cross-product dose-conversion table as a procurement shortcut.
Expert quote — reserved: ________________________________________
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq